RxDoctor Payments Data

Hajra Awwab, MD

Cardiology · Providence, RINPI 1073969424

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (41.3%), grants and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 67.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $19,181 and has fallen 65.4% since, to $6,631 in 2025.

$48,049in general payments, 2019–2025

Across 205 payments — averaging $234.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$32K
  • Biotronik Inc.$10K
  • Boston Scientific$4K
  • Medical Device Business Services, Inc.$1K
  • Abbott$372
  • Atricure, Inc.$170
  • plus $185 from 7 others

What the payments were for

  • Grants$18,75039%
  • Travel & lodging$19,84041%
  • Food & beverage$8,55918%
  • Education$9012%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,021
Medicare patients
222
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$51,284
Amiodarone Hcl22$779
Metoprolol Succinate46$759
Pantoprazole Sodium25$257
Metoprolol Tartrate32$255
Sucralfate11$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$51,28440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.

Other cardiology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →